Abstract
Introduction: Ticagrelor is an oral P2Y12 receptor antagonist commonly used in the management of acute coronary syndrome. However, it may cause QT interval prolongation, potentially leading to life-threatening arrhythmias such as torsades de pointes and ventricular fibrillation, especially in high-risk patients.
Case report: We report the case of a 62-year-old male patient diagnosed with non-ST elevation myocardial infarction who developed QT interval prolongation, torsades de pointes, and ventricular fibrillation following the administration of ticagrelor. The arrhythmias resolved after discontinuation of the drug.
Conclusion: Ticagrelor-induced QT prolongation and torsades de pointes are not uncommon in clinical settings. Risk stratification and close monitoring of the QT interval in high-risk patients are crucial for the timely prevention and management
Of these potentially fatal arrhythmias.